Table 1.
Pathologic features and engraftment rates of RCC cases in this study
| Case | Sex | Age | Pathologic stage | Nodal and metastatic stage | Fuhrman grade | Additional pathologic features | TSG engraftment rate (engrafted/total) |
|---|---|---|---|---|---|---|---|
| 1 | F | 64 | T3a | NxMx | III | 90% (25/28) 100% (5/5)a | |
| 2 | F | 33 | T3b | N1Mx | IV | Sarcomatoid | 82% (27/33) 100% (5/5)a |
| 3 | M | 75 | T2a | NxMx | III/IV | Rhabdoid, papillary | 79% (23/29) 100% (3/3)a |
| 4 | F | 76 | T1a | NxMx | II | 100% (12/12) | |
| 5 | F | 91 | T1a | NxMx | III | 100% (5/5) | |
| 6 | M | 62 | T3a | NxMx | III | 100% (10/10) | |
| 7 | M | 68 | T3a | NxMx | Chromophobe | 100% (5/5) | |
| 8 | M | 91 | T3a | NxM1 | III | 100% (10/10) | |
| 9 | M | 61 | T3a | NxMx | II | 100% (3/3) | |
| 10 | F | 83 | T3a | NxMx | II | Sarcomatoid | 100% (3/3) |
| 11 | M | 59 | T1b | NxMx | II | 33% (1/3) | |
| 12b | F | 59 | T3a | NxM1 | IV | Rhabdoid | 66% (19/29) |
| 13 | M | 42 | T3a | NxMx | III | 45% (9/20) |
a
Secondary TSGs generated from primary TSGs.
b
Patient received neoadjuvant therapy of 4 cycles of sunitinib (37.5–50 mg/day, 2 wks on and 1 wk off), which was completed 2 weeks prior to surgery.